Back to Ovarian Cancer
NCT02661932
NCT02661932
Who may be able to join
Who might be able to join this trial:
- You are a woman with breast cancer who is under 41 years old
- You have been referred to a fertility preservation service before starting chemotherapy
Who may not be able to join:
- Your breast cancer has spread to other parts of the body (metastatic breast cancer)
- You have already been diagnosed with early menopause or premature ovarian failure
- Your baseline FSH (a hormone level measured by a blood test) is above 20 IU — this is a measure of ovarian function (confirm with trial site)
- You have a medical condition that means surgery would not be safe for you
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 4: approximately Approved of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Completed
Phase
Phase 4
Sponsor
Erasme University Hospital
Registry
clinicaltrials_gov
Start date
1 November 2012
Est. completion
1 March 2018
Where this trial is recruiting
🇧🇪 Belgium
Primary endpoints
Oocyte maturation rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.